Partnership enables oncologists in Singapore,
Malaysia, Thailand, Vietnam and The Philippines to offer patients a
new standard of care through GPS Cancer
NantHealth expands global GPS Cancer launch
with test now also internationally available in Israel, Mexico,
Italy and the Middle East
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation,
evidence-based, personalized healthcare company, announced
that it has entered into an agreement for GPS Cancer, the
leading proteogenomic molecular test that helps guide treatment
strategies including choice of standard chemotherapy for
oncologists, with Asia Genomics, a leading provider and
distributor of molecular testing services and key player in the
field of personalized medicine in Southeast Asia.
It is estimated that there were over 770,000 new cases of cancer
and 527,000 cancer deaths in the Southeast Asia region in 2012. By
2030, the number of new cases is expected to rise by 70 percent,
reaching 1.3 million people. More than 75 percent of people with
cancer in Southeast Asian countries experience death or financial
catastrophe within a year of diagnosis. With little evidence
available to articulate the economic impact of cancer on low and
middle-income households, and its relationship to treatment and
health outcomes, a profound lack of understanding surrounds the
burden of the disease. [1]
“While cancer incidences continue to increase worldwide, GPS
cancer is leading the evolution from a ‘one size fit all’ treatment
approach to the era of proteogenomics and quantitative proteomics,”
said Dr. Patrick Soon-Shiong, founder and CEO of NantHealth.
“Through the exclusive partnership with Asia Genomics, GPS cancer
is offered for the first time in Southeast Asia. This is an
important step in the global expansion of GPS cancer and we’re
excited to be bringing a much needed alternative to transform the
way that cancer is treated in this region.”
Unlike other tests on the market, GPS Cancer sequences the whole
genome of 20,000+ genes and three billion base pairs and matches
against the patient’s normal DNA, providing oncologists with an
expansive view of alterations to inform personalized treatment
strategies. GPS Cancer extends from genomics to proteomics not only
through analysis of RNA, but also utilizes quantitative proteomics
through mass spectrometry to measure the amounts of clinically
relevant proteins that are the targets of or essential for various
therapeutics. This clinically relevant information helps
oncologists to better understand how patients may potentially
respond to chemotherapies, targeted therapies and
immunotherapies.
Under the terms of the agreement, Asia Genomics will
distribute GPS Cancer to physicians in the following Southeast
Asian countries: Singapore, Malaysia, Thailand, Vietnam and the
Philippines. Asia Genomics is the first company to build
comprehensive distribution channels in Southeast Asia for
personalized medicine testing services. The company has also
developed a broad network with government and regulatory entities,
local oncology communities, hospitals, clinics and pathology labs,
influencers, as well as research communities to advance local
healthcare service offerings.
“GPS cancer is a revolutionary test that can help identify
treatment options based on patients’ unique biology profile,” said
Dr. Wong Mun Yew, CEO at Asia Genomics. “We’re looking forward to
offering patients a new standard of care that will ultimately
change the way we diagnose and treat cancer not only in Southeast
Asia, but worldwide.”
About Asia
Genomics (www.asia-genomics.com)Asia
Genomics is a leading molecular diagnostics company focused on
molecular biology and genomics to transform the healthcare industry
in Asia. The Company offers tests that are evidence-based, accepted
and endorsed by doctors internationally. Based in Singapore, with
operations in Malaysia, Philippines, Vietnam, Indonesia, China,
Hong Kong and Thailand, Asia Genomics has two laboratories, and a
total market reach of more than 1.5 billion people.
Cautionary Note Concerning Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding the capabilities and
anticipated utility of our GPS Cancer, including predicting patient
response and resistance to therapeutics, enabling diagnoses by
physicians and accelerating efforts to bring novel combinations of
therapeutic agents to cancer patients. Forward-looking statements
are subject to numerous risks and uncertainties that could cause
actual results to differ materially from currently anticipated
results. Factors that may cause future results to differ materially
from management’s current expectations include, among other things,
that GPS Cancer may not perform as anticipated, that sufficient
physicians may not adopt GPS Cancer to assist their diagnoses or
that healthcare payers may not provide reimbursement for GPS Cancer
as expected. Our business is subject to numerous additional risks
and uncertainties, including, among others, risks relating to
market acceptance of our products; our ability to successfully
launch new products and applications; competition; our sales,
marketing and distribution capabilities; our planned sales,
marketing, and research and development activities; unanticipated
increases in costs or expenses; and risks associated with
international operations. Information on these and additional
risks, uncertainties, and other information affecting our business
and operating results can be found in our existing and future
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. We
disclaim any obligation to update these forward-looking statements
except as may be required by law.
About GPS Cancer™GPS Cancer™ is a unique, proteogenomic
molecular scan available through NantHealth. GPS Cancer integrates
whole genome (DNA) sequencing, whole transcriptome (RNA)
sequencing, and quantitative proteomics through mass spectrometry,
providing oncologists with a comprehensive molecular profile of a
patient's cancer and an assessment of protein pathway function to
inform personalized treatment strategies. GPS Cancer scanning is
conducted in CLIA-certified and CAP-accredited laboratories, and is
a key enabler for Cancer Breakthroughs 2020, the world's most
comprehensive cancer collaborative initiative seeking to accelerate
the potential of combination immunotherapy as the next generation
standard of care in cancer patients. For more information,
visit www.gpscancer.com.
About NantHealth, Inc.NantHealth, Inc., a member of the
NantWorks ecosystem of companies, is a next-generation,
evidence-based, personalized healthcare company enabling improved
patient outcomes and more effective treatment decisions for
critical illnesses. NantHealth's unique systems-based approach to
personalized healthcare applies novel diagnostics tailored to the
specific molecular profiles of patient tissues and integrates this
molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system, which includes its unique
software, middleware and hardware systems infrastructure that
collects, indexes, analyzes and interprets billions of molecular,
clinical, operational and financial data points derived from novel
and traditional sources, continuously improves decision-making and
further optimizes our clinical pathways and decision algorithms
over time. For more information please
visit www.nanthealth.com and follow Dr. Soon-Shiong on
Twitter @DrPatSoonShiong.
[1] http://partnerships.ifpma.org/partnership/the-action-study-understanding-the-impact-of-cancer-in-southeast-asia
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170830005244/en/
NantWorksJen Hodsonjhodson@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024